Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Overview
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Companies Involved in Therapeutics Development
Evotec AG
Mateon Therapeutics Inc
Medivir AB
Virobay Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Drug Profiles
KGP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIV-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CTSK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Dormant Products
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Discontinued Products
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Product Development Milestones
Featured News & Press Releases
Oct 19, 2018: New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21
Jul 27, 2018: MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure
Jun 28, 2018: Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension Study
Apr 26, 2018: Medivir AB: Data From the MIV-711 Initial Phase IIa Study Will be Presented at the OARSI World Congress on April 27
Nov 09, 2017: MIV-711 phase IIa osteoarthritis study data presented as a late breaking poster at the Annual Meeting of the American College for Rheumatology
Oct 24, 2017: Medivir Receives FDA Fast Track Desigtion for MIV-711 for the Treatment of OA
Oct 20, 2017: MIV-711 phase IIa osteoarthritis study data selected as late breaking abstract at the Annual Meeting of the American College for Rheumatology
Sep 25, 2017: Medivir announces Positive Topline Results from phase IIA osteoarthritis study, showing disease-modifying benefit of MIV-711 on joint structure
Sep 14, 2017: Data monitoring committee gives “Go Ahead” in the MIV-711 osteoarthritis extension study
Aug 16, 2017: FDA accepts Medivir?s IND application for MIV-711, ebling clinical development in the US
Jun 09, 2017: Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation to "Go Ahead"
Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data ebles trial continuation without any modifications
Dec 08, 2016: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues Without any Modifications
Oct 27, 2016: MIV-711 osteoarthritis program: Enrollment in the phase IIa study is complete and independent safety review committee again recommends Go Ahead
Sep 23, 2016: Medivir: MIV-711 Osteoarthritis Trial: Recommendation to Go Ahead Based on Independent Review of Safety Data, and First Patient Enrolled in Extension Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Evotec AG, H1 2019
Pipeline by Mateon Therapeutics Inc, H1 2019
Pipeline by Medivir AB, H1 2019
Pipeline by Virobay Inc, H1 2019
Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019